Who owns 4D Molecular Therapeutics In (FDMT)?
94 US mutual funds and ETFs from 54 fund families reported a position in FDMT for the quarter ending 2026-06-30. Against their own report a quarter earlier, 39 raised shares, 12 opened a new position, 19 cut and 4 sold out.
Largest fund families
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Ishares Trust | 6 | 22.8% |
| Vanguard Index Funds | 2 | 21.5% |
| Spdr Series Trust | 2 | 19.8% |
| Janus Investment Fund | 1 | 8.3% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1 | 7.1% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1 | 4.8% |
Tracked managers holding FDMT
None of the managers Prior Moves tracks on 13F reports FDMT in its latest filing.
Source: SEC Form N-PORT, which funds file about 60 days after quarter end, and the latest 13F filings. Share counts, not trades: a change can reflect fund inflows or outflows rather than a decision about FDMT. A record of holdings, not a forecast and not investment advice. See all owner pages or the forecast board for the names our model ranks.
Our model ranks every tracked manager’s likely next buys from 13F filings. Request the dataset sample with a work email.
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.